NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 3 FDA
NCT03906331 2025-01-17Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationEli Lilly and CompanyApproved for marketing
NCT05500508 2024-12-24Oral AMXT 1501 Dicaprate in Combination With IV DFMOAminex Therapeutics, Inc.Phase 1/2 Terminated15 enrolled